Biopsy Collection and Repository Database
BICARD
Cardiac Biopsy Collection Repository and Database
1 other identifier
observational
400
1 country
1
Brief Summary
Use samples procured from patients to improve understanding of molecular, cellular, and tissue-level processes produced by a variety of cardiac diseases and therapeutic interventions.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2021
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 21, 2021
CompletedFirst Submitted
Initial submission to the registry
August 20, 2022
CompletedFirst Posted
Study publicly available on registry
August 30, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2030
February 3, 2026
January 1, 2026
9 years
August 20, 2022
January 30, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Discover and quantify the concentration of novel diagnostic and prognostic biomarkers
Use biospecimens procured from patients with cardiac conditions to identify diagnostic surrogate biomarkers using discovery proteomics. In Cardiac Amyloidosis, the serum levels will be compared between confirmed ATTR and non-ATTR heart failure patients and a diagnostic threshold will be established. The research aims to advance understanding of cardiac diseases and to support the development of improved therapies.
12/21/2021-12/31/2030
Study Arms (1)
Biological specimens
Biological specimens taken from cardiovascular procedures
Eligibility Criteria
All patients undergoing evaluation of a cardiac condition or receiving a right heart catheterization with biopsy clinically indicated who are at least 18 years of age.
You may qualify if:
- All patients undergoing evaluation of a cardiac condition or receiving a right heart catheterization with biopsy clinically indicated who are at least 18 years of age.
You may not qualify if:
- Patients without a cardiovascular or amyloidosis diagnosis, under 18 years of age.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Kentucky
Lexington, Kentucky, 40536, United States
Biospecimen
During this study, tissue samples (blood, urine and/or myocardial tissue) will be used to help identify trends in biomarkers and other information for patients with Cardiac Amyloidosis and other Cardiovascular conditions. No clinically important information that could be used by the subject will be identified. Therefore, the results of these studies will not be shared with the subjects.
MeSH Terms
Conditions
Study Officials
- PRINCIPAL INVESTIGATOR
Kenneth S Campbell, PhD
University of Kentucky
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
August 20, 2022
First Posted
August 30, 2022
Study Start
December 21, 2021
Primary Completion (Estimated)
December 1, 2030
Study Completion (Estimated)
December 1, 2030
Last Updated
February 3, 2026
Record last verified: 2026-01